Program
CD47 Antagonist AUR103 Calcium
Its studies are mostly in Neoplasms · Stomach Neoplasms, led by Dr. Reddy's Laboratories.
Furthest: phase 2, since Jun 4, 20252 company-led studies, 1 open or runningNext primary completion: Dec 30, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dr. Reddy's Laboratories | 21 open or running | phase 2since Jun 4, 2025 | Jun 4, 2025 | Dec 30, 2028phase 2 · NCT07640737 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 4, 2025First study: phase 2 study in HER 2 Positive Gastric CancerFirst studyNCT07040059 · 2 enrolled · India
- Jun 3, 2026Phase 2 study in NeoplasmsNCT07640737 · 30 planned · United States
Ahead
- Dec 30, 2028Primary completion: phase 2 study in NeoplasmsNCT07640737
TargetBeta
CD47 →read by rule
“The calcium salt form of AUR103, an orally bioavailable, small molecule antagonist of the human cell surface antigen CD47, ”NCIt, by rule
Other programs on CD47
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ligufalimabrule | Akeso | phase 3 | 11 |
| evorpaceptrule | alx-oncology-inc | phase 3 | 9 |
| Anti-PD-1/CD47 Fusion Protein HX009rule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 5 |
| 1200mg of tqb2928 injection | Sino Biopharmaceutical | phase 1 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07640737Neoplasms · United States | 2 | Not yet recruiting | Dec 30, 2028 | 30 |
| NCT07040059HER 2 Positive Gastric Cancer · India | 2 | Terminated | Dec 29, 2025 | 2 |
How it is read
Names in the registry
- “AUR103 Calcium”, 2 entries
Conditions, from the studies’ own filings
- Neoplasms, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.